Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis

MeSH terms

• Alemtuzumab
• Antibodies, Monoclonal / adverse effects*
• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Humanized
• Antibodies, Monoclonal, Murine-Derived / therapeutic use
• Antibodies, Neoplasm / adverse effects*
• Antibodies, Neoplasm / therapeutic use*
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Autoimmunity / physiology
• Biopsy
• Cyclophosphamide / administration & dosage
• DNA, Viral / blood
• Doxorubicin / administration & dosage
• Epstein-Barr Virus Infections / complications*
• Herpesvirus 4, Human / genetics
• Herpesvirus 4, Human / physiology*
• Humans
• Lymphoproliferative Disorders / drug therapy
• Lymphoproliferative Disorders / virology*
• Male
• Middle Aged
• Muscle, Skeletal / pathology
• Polymyositis / drug therapy*
• Polymyositis / immunology
• Polymyositis / pathology
• Prednisone / administration & dosage
• Remission Induction
• Rituximab
• Treatment Outcome
• Vincristine / administration & dosage